Aptevo Therapeutics (NASDAQ:APVO – Get Rating) announced its earnings results on Thursday. The biotechnology company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.40), Fidelity Earnings reports. Aptevo Therapeutics had a negative return on equity of 357.62% and a negative net margin of 231.51%.
APVO opened at $4.60 on Friday. The company has a debt-to-equity ratio of 3.05, a quick ratio of 1.51 and a current ratio of 1.51. The stock’s fifty day simple moving average is $4.96 and its 200 day simple moving average is $7.18. Aptevo Therapeutics has a 1-year low of $3.45 and a 1-year high of $31.76.
A number of research firms recently issued reports on APVO. Piper Sandler lowered their target price on Aptevo Therapeutics from $69.00 to $20.00 in a research report on Friday. StockNews.com cut shares of Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Zacks Investment Research upgraded shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a research note on Tuesday, March 29th.
About Aptevo Therapeutics (Get Rating)
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome.
- Get a free copy of the StockNews.com research report on Aptevo Therapeutics (APVO)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.